Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 6/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.70 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10309037 | 1.00 | CYP1A1 (0.70) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL10309019 | 0.87 | RAB9A (0.66) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL10275087 | 0.87 | RAB9A (0.66) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL10275039 | 0.85 | CYP1A1 (0.70) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL17233301 | 0.83 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL10275468 | 0.82 | RAB9A (0.66) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL10309020 | 0.82 | RAB9A (0.66) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL9434333 | 0.80 | RAB9A (0.60) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL10275037 | 0.80 | CYP1A1 (0.74) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 | |
| SCHEMBL10309040 | 0.80 | CYP1A1 (0.74) | CYP1A1CYP1A2CYP1B1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312728-A1 | Methods and Compositions for Diabetes Treatment and Beta-Cell Regeneration | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | US | disclosed |
| CN-116615241-A | Methods and compositions for diabetes treatment and beta cell regeneration | 加利福尼亚大学董事会 | 2023-08-18 | — | — | CN | disclosed |
| US-10010542-B2 | PFKFB3 inhibit and methods of use as an anti-cancer therapeutic | GB ACT, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170258783-A1 | PFKFB3 INHIBIT AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | GB005, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9649305-B2 | PFKFB3 inhibitor and methods of use as an anti-cancer therapeutic | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2831047-B1 | PFKFB3 INHIBITOR AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | ADVANCED CANCER THERAPEUTICS LLC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20150064175-A1 | PFKFB3 INHIBITOR AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | GB005, INC. | 2015-03-05 | — | — | US | disclosed |
| US-8557823-B2 | Family of PFKFB3 inhibitors with anti-neoplastic activities | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258783-A1 | PFKFB3 INHIBIT AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | PFKFB3, PFKFB1, PFKFB2 | CYP1A1 3075/4885CYP1A2 2493/4885CYP1B1 2579/4885 |
| US-20120177749-A1 | FAMILY OF PFKFB3 INHIBITORS WITH ANTI-NEOPLASTIC ACTIVITIES | PFKFB3, PFKFB2, PFKFB1 | CYP1A1 4826/4885CYP1A2 4666/4885CYP1B1 4552/4885 |
| US-10010542-B2 | PFKFB3 inhibit and methods of use as an anti-cancer therapeutic | PFKFB3, PFKFB1, PFKFB2 | CYP1A1 3075/4885CYP1A2 2493/4885CYP1B1 2579/4885 |
| US-20150064175-A1 | PFKFB3 INHIBITOR AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | PFKFB3, PFKFB1, PFKFB2 | CYP1A1 2919/4885CYP1A2 2362/4885CYP1B1 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.